Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Cupping may ease short-term pain, disability

21 Nov 2020
The rise of cupping: Olympians spotted with bruises on their bodies

Cupping seems to help ease short-term pain intensity and disability, reports a recent meta-analysis, although further studies are needed due to high clinical heterogeneity and risks of bias in the existing literature.

From the databases of PubMed, the Cochrane Library, and Scopus, researchers retrieved 18 randomized controlled trials (RCTs) that looked at the impact of any cupping intervention on adult patients with chronic pain conditions, including lower back or neck pain, rheumatoid arthritis, fibromyalgia, neuropathic pain, osteoarthritis, or headaches/migraines.

Cupping had a strong and significant short-term impact on pain intensity relative to no treatment (standardized mean difference [SMD], –1.03, 95 percent confidence interval [CI], –1.41 to –0.65; p<0.00001), but not against sham cupping (SMD, –0.27, 95 percent CI, –0.58 to 0.05; p=0.09) or active treatment (SMD, –0.24, 95 percent CI, –0.57 to 0.09; p=0.15).

Similarly, cupping yielded a medium-sized short-term benefit in terms of disability as compared with no treatment (SMD, –0.66, 95 percent CI, –0.99 to –0.34; p=0.0002). Cupping was likewise significantly better for disability relative to other active treatments (SMD, –0.52, 95 percent CI, –1.03 to –0.0028; p=0.05), but no advantage over sham cupping was detected (SMD, –0.26, 95 percent CI, –0.57 to 0.05; p=0.10).

However, the researchers detected concerns regarding evidence quality. Heterogeneity, especially in the comparison between cupping and no treatment, was significant for both pain intensity and disability outcomes. The risk of bias was also high in most studies, particularly in terms of blinding of participants and personnel and of outcome assessments.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.